Alexander Lemaire leads process development at Strand Therapeutics, shaping strategy and execution for mRNA and lipid nanoparticle manufacturing from concept to clinic. He builds scalable, phase-appropriate processes, defines control strategies, and steers tech transfer and external manufacturing partnerships. His work emphasizes platformization, throughput, and operational excellence—leveraging automation, digital tools, and design-of-experiments to compress timelines and reduce COGs while maintaining quality. Alexander collaborates across discovery, quality, regulatory, and supply to align roadmaps, de-risk programs, and deliver CMC packages that enable development milestones. Earlier in his career he supported analytical method development to ensure fit-for-purpose characterization and release—experience that informs his pragmatic approach to process design. He holds a B.S. in Biology.
